Peptides
GLP-1s Move Beyond Weight Loss: Parkinson's, Kidneys, Eyes, and the Brain
A phase 3 Parkinson's trial, a kidney meta-analysis, an ocular cohort and new mechanistic work suggest the GLP-1 class is becoming a multi-system intervention — with important caveats.